169 related articles for article (PubMed ID: 19711075)
61. IL-8 as mediator in the microenvironment-leukaemia network in acute myeloid leukaemia.
Kuett A; Rieger C; Perathoner D; Herold T; Wagner M; Sironi S; Sotlar K; Horny HP; Deniffel C; Drolle H; Fiegl M
Sci Rep; 2015 Dec; 5():18411. PubMed ID: 26674118
[TBL] [Abstract][Full Text] [Related]
62. CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells.
Jitschin R; Saul D; Braun M; Tohumeken S; Völkl S; Kischel R; Lutteropp M; Dos Santos C; Mackensen A; Mougiakakos D
J Immunother Cancer; 2018 Nov; 6(1):116. PubMed ID: 30396365
[TBL] [Abstract][Full Text] [Related]
63. Expression patterns of costimulatory molecules on cells derived from human hematological malignancies.
Zheng Z; Takahashi M; Aoki S; Toba K; Liu A; Osman Y; Takahashi H; Tsukada N; Suzuki N; Nikkuni K; Furukawa T; Koike T; Aizawa Y
J Exp Clin Cancer Res; 1998 Sep; 17(3):251-8. PubMed ID: 9894758
[TBL] [Abstract][Full Text] [Related]
64. Retrovirus-mediated IL-7 expression in leukemic dendritic cells generated from primary acute myelogenous leukemias enhances their functional properties.
Bello-Fernández C; Stasakova J; Renner A; Carballido-Perrig N; Koening M; Waclavicek M; Madjic O; Oehler L; Haas O; Carballido JM; Buschle M; Knapp W
Blood; 2003 Mar; 101(6):2184-90. PubMed ID: 12424204
[TBL] [Abstract][Full Text] [Related]
65. Inducibility of lymphokine activated killer (LAK) cells in patients with acute myelogenous leukaemia in complete remission and its clinical relevance.
Archimbaud E; Bailly M; Doré JF
Br J Haematol; 1991 Mar; 77(3):328-34. PubMed ID: 2012757
[TBL] [Abstract][Full Text] [Related]
66. [T-cell immunity against autologous leukemic cell mediated by in vitro bone marrow-derived dendritic cell from patients with acute myeloid leukemia in complete remission].
He X; You S; Bian S
Zhonghua Xue Ye Xue Za Zhi; 2001 Dec; 22(12):629-32. PubMed ID: 16200709
[TBL] [Abstract][Full Text] [Related]
67. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies.
Graf M; Hecht K; Reif S; Pelka-Fleischer R; Pfister K; Schmetzer H
Eur J Haematol; 2004 Feb; 72(2):89-106. PubMed ID: 14962246
[TBL] [Abstract][Full Text] [Related]
68. The imbalanced profile and clinical significance of T helper associated cytokines in bone marrow microenvironment of the patients with acute myeloid leukemia.
Sun YX; Kong HL; Liu CF; Yu S; Tian T; Ma DX; Ji CY
Hum Immunol; 2014 Feb; 75(2):113-8. PubMed ID: 24269703
[TBL] [Abstract][Full Text] [Related]
69. Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma.
Antonia SJ; Seigne J; Diaz J; Muro-Cacho C; Extermann M; Farmelo MJ; Friberg M; Alsarraj M; Mahany JJ; Pow-Sang J; Cantor A; Janssen W
J Urol; 2002 May; 167(5):1995-2000. PubMed ID: 11956426
[TBL] [Abstract][Full Text] [Related]
70. Interleukin-15-Cultured Dendritic Cells Enhance Anti-Tumor Gamma Delta T Cell Functions through IL-15 Secretion.
Van Acker HH; Anguille S; De Reu H; Berneman ZN; Smits EL; Van Tendeloo VF
Front Immunol; 2018; 9():658. PubMed ID: 29692776
[TBL] [Abstract][Full Text] [Related]
71. Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells.
Curti A; Pandolfi S; Aluigi M; Isidori A; Alessandrini I; Chiodoni C; Testoni N; Colombo MP; Baccarani M; Lemoli RM
Exp Hematol; 2005 Dec; 33(12):1521-30. PubMed ID: 16338495
[TBL] [Abstract][Full Text] [Related]
72. Generating Peripheral Blood Derived Lymphocytes Reacting Against Autologous Primary AML Blasts.
Mehta RS; Chen X; Antony J; Boyiadzis M; Szabolcs P
J Immunother; 2016; 39(2):71-80. PubMed ID: 26849076
[TBL] [Abstract][Full Text] [Related]
73. HLA identical leukemia cells and T cell growth factor activate cytotoxic T cell recognition of minor locus histocompatibility antigens in vitro.
Sondel PM; Hank JA; Wendel T; Flynn B; Bozdech MJ
J Clin Invest; 1983 Jun; 71(6):1779-86. PubMed ID: 6223050
[TBL] [Abstract][Full Text] [Related]
74. Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia.
Folgiero V; Goffredo BM; Filippini P; Masetti R; Bonanno G; Caruso R; Bertaina V; Mastronuzzi A; Gaspari S; Zecca M; Torelli GF; Testi AM; Pession A; Locatelli F; Rutella S
Oncotarget; 2014 Apr; 5(8):2052-64. PubMed ID: 24903009
[TBL] [Abstract][Full Text] [Related]
75. High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML).
Graf M; Reif S; Hecht K; Pelka-Fleischer R; Kroell T; Pfister K; Schmetzer H
Ann Hematol; 2005 May; 84(5):287-97. PubMed ID: 15592672
[TBL] [Abstract][Full Text] [Related]
76. A CD80-transfected human breast cancer cell variant induces HER-2/neu-specific T cells in HLA-A*02-matched situations in vitro as well as in vivo.
Gückel B; Stumm S; Rentzsch C; Marmé A; Mannhardt G; Wallwiener D
Cancer Immunol Immunother; 2005 Feb; 54(2):129-40. PubMed ID: 15365776
[TBL] [Abstract][Full Text] [Related]
77. Interferon-gamma enhances growth factor-dependent proliferation of clonogenic cells in acute myeloblastic leukemia.
Murohashi I; Hoang T
Blood; 1991 Aug; 78(4):1085-95. PubMed ID: 1714325
[TBL] [Abstract][Full Text] [Related]
78. PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells.
Ni X; Song Q; Cassady K; Deng R; Jin H; Zhang M; Dong H; Forman S; Martin PJ; Chen YZ; Wang J; Zeng D
J Clin Invest; 2017 May; 127(5):1960-1977. PubMed ID: 28414296
[TBL] [Abstract][Full Text] [Related]
79. Immune stimulatory potential of B7.1 and B7.2 retrovirally transduced melanoma cells: suppression by interleukin 10.
Dummer R; Yue FY; Pavlovic J; Geertsen R; Döhring C; Moelling K; Burg G
Br J Cancer; 1998 May; 77(9):1413-9. PubMed ID: 9652756
[TBL] [Abstract][Full Text] [Related]
80. Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells.
Barbui AM; Borleri G; Conti E; Ciocca A; Salvi A; Micò C; Introna M; Rambaldi A
Exp Hematol; 2006 Apr; 34(4):475-85. PubMed ID: 16569594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
